Search filters

Filters
Clear All

Phase

  • 2
  • 6
  • 1
  • 5
  • 7
  • 23
  • 10
  • 23

Found 23 Pancreatitis trials

A listing of Pancreatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 65 years
All genders
Phase 1/2
Interventional
This study investigates the safety and efficacy of implanting pancreatic endocrine cell clusters into the omentum of patients with Type 1 diabetes who experience severe hypoglycemia. The study aims to evaluate how well the treatment works and how long it lasts, along with determining the best dose. Participants will need …
18 years or above
All genders
Observational
This study will be a retrospective chart review of patients who have been diagnosed with benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, Texas. The Investigators plan to …
 Does Apolipoprotein A-V (APOA5) the genetic code of a protein, affect the levels of triglycerides (a type of fat) in the blood,
18 years - 99 years
All genders
The purpose of this study is to determine how changes in the genetic code of a protein called Apolipoprotein A-V (APOA5) may affect the levels of triglycerides (a type of fat) in the blood, and the risk of heart disease and acute pancreatitis. People who have these changes, as well …
18 years - 99 years
All genders
Phase 1
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
 REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma
18 years - 99 years
All genders
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
 The Cancer of the Pancreas Screening-5
1 years - 99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
99 years or below
All genders
Phase 2
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation
18 years - 99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
12 years - 99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
11 - 20 of 23